Ticker Details
Agenus Inc. Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.
IPO Date:	February 4, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$110.59M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.12 | 3.44%
Avg Daily Range (30 D):	$0.15 | 4.16%
Avg Daily Range (90 D):	$0.12 | 3.09%

Institutional Daily Volume
Avg Daily Volume:	.32M
Avg Daily Volume (30 D):	.68M
Avg Daily Volume (90 D):	.57M

Trade Size
Avg Trade Size (Sh.):	63
Avg Trade Size (Sh.) (30 D):	139
Avg Trade Size (Sh.) (90 D):	128

Institutional Trades
Total Institutional Trades:	1,261
Avg Institutional Trade:	$1.65M
Avg Institutional Trade (30 D):	$.51M
Avg Institutional Trade (90 D):	$.51M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.76M
Avg Closing Trade (30 D):	$.64M
Avg Closing Trade (90 D):	$.64M
Avg Closing Volume:	38.91K

News

Feb 18, 2026 @ 4:00 PM CTLA-4 Inhibitors Competitive Landscape Research R... Source: Researchandmarkets.Com

Jan 5, 2026 @ 11:04 PM Agenus (AGEN) Q3 2024 Earnings Call Transcript Source: Motley Fool Transcribing

Aug 28, 2025 @ 2:44 PM FDA Tightens Survival Standards as Cancer Drug Pip... Source: Prnewswire

Aug 18, 2025 @ 5:00 PM PD-(L)1 Inhibitors Market Set to Surge During the ... Source: Delveinsight

Aug 13, 2025 @ 2:00 PM U.S. Pharmaceutical CDMO Market Valuation to Surpa... Source: Towards Healthcare

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.97	$2	$-1
Diluted EPS	$-2.03	$1.94	$-1
Revenue	$106.83M	$30.24M	$25.69M
Gross Profit	$105.69M	$29.59M	$25.45M
Net Income / Loss	$-39.28M	$63.91M	$-30.01M
Operating Income / Loss	$-60.46M	$-4.55M	$-16.71M
Cost of Revenue	$1.14M	$.64M	$.24M
Net Cash Flow	$-43.25M	$-7.98M
PE Ratio

Splits
Apr 12, 2024	1:20
Oct 03, 2011	1:6